Exploring the inner life of GPCRs to create and tailor new therapeutics for endocrine disorders and endocrine-related cancers.
WE ARE CRINETICS
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
WE ARE CRINETICS
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Location: United States, California, San Diego
Employees: 51-200
Phone: (858) 450-6464
Total raised: $106.3M
Founded date: 2008
Investors 5
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Perceptive... | perceptive... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.03.2018 | Series B | $63.5M | - |
| 13.07.2017 | Grant | $2.8M | - |
| 20.11.2015 | Series A | $40M | - |
Mentions in press and media 22
| Date | Title | Description |
| 08.08.2024 | Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent Cushing’s Syndrome Expected by End of 2024 Ma... |
| 12.03.2024 | Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome | Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Res... |
| 12.03.2024 | Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome | - |
| 11.03.2024 | Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | - |
| 11.03.2024 | Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to pu... |
| 28.02.2024 | Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024 Announced a $350 Mil... |
| 17.08.2023 | Startup is developing a pill intended to help large dogs live longer | San Francisco-based Loyal is working on a new drug it hopes will help large dogs live healthier, longer lives. Driving the news: Loyal recently partnered with pharmaceutical company Crinetics to get exclusive veterinary access to its compou... |
| 04.05.2023 | Pioneering Pharmaceutical Company Supports Next Generation with Unique Employee Benefit | TOOTRiS Child Care On-Demand TOOTRiS Child Care On-Demand and Crinetics Pharmaceuticals partner to provide child care benefits to new and current employees SAN DIEGO, CALIFORNIA, UNITED STATES, May 4, 2023/EINPresswire.com/ -- As 1 in 3 wor... |
| 12.01.2022 | Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference | - Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 - - Initiat... |
| 28.10.2021 | Radionetics Oncology Launches with $30M Investment | Photo Courtesy of Crinetics San Diego-based Crinetics Pharmaceuticals focuses on discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Radionetics Oncology, a pharmaceutical c... |
Show more